Avoid common mistakes on your manuscript.
Correction to: Infect Dis Ther https://doi.org/10.1007/s40121-021-00455-1
In the Original publication of the article the key summary points were incorrectly published.
This has been corrected here.
Key Summary Points
Why carry out this study | |
The global elimination of HCV infection is a possibility with the availability of short-course pangenotypic direct-acting antivirals, however rapid expansion of treatment to historically marginalized patients is necessary to achieve the goal of elimination. | |
This multinational study presents the efficacy, safety, and patient-reported outcomes of treatment with G/P in historically underserved patient populations in real-world settings. | |
What was learned from the study? | |
Overall, G/P treatment was highly effective with a cure rate of 98% and well-tolerated across a broad range of marginalized patients with chronic HCV and single or dual comorbidities. | |
Results from this real-world analysis address current gaps in clinical knowledge regarding impact on quality of life and G/P treatment led to improvements in health-related quality of life and reductions in fatigue. | |
These results further support the use of an 8-week short-course G/P in underserved patients including those with substance abuse and psychiatric comorbidities. |
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Aghemo, A., Horsmans, Y., Bourgeois, S. et al. Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir. Infect Dis Ther 10, 2223–2225 (2021). https://doi.org/10.1007/s40121-021-00529-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40121-021-00529-0